Elpiscience Biopharmaceuticals
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies.
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies.
Elpiscience Biopharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing next-generation cancer immunotherapies. Founded in 2017 and headquartered in China, the company is dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide.
Their innovative approach targets the adenosine pathway and myeloid checkpoints to remove immunosuppressive factors in the tumor microenvironment. The company has developed a pipeline of novel molecules using proprietary platforms, including the powerful Bispecific Macrophage Engager (BiME®) technology, which activates macrophages for solid tumor killing without causing cytokine storms.
In its latest funding round, Elpiscience secured a substantial $105.00M Series C investment on 13 May 2021. The investors in this round included Lilly Asia Ventures, CDH Investments, Dyee Capital, Maison Capital, Oriza Holdings, Cormorant Asset Management, Superstring Capital, Greater Bay Area Homeland Development Fund, Keyuan Industry Fund, and Zero2IPO, demonstrating strong support and confidence in Elpiscience's innovative approaches within the biopharma, biotechnology, health care, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $105.00M | 10 |
|
13 May 2021 |
| Series B | $100.00M | - | 28 Dec 2019 | |
| Series A | $35.00M | - | 03 Dec 2018 | |
| Series A | $20.00M | - | 03 Apr 2017 |
No recent news or press coverage available for Elpiscience Biopharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
